1. In Vivo
  2. >>Innovation

A Virtuous Cycle: What The Immuno-Oncology Revolution Means For Other Disease Areas

 
• By Emily Hayes

Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.

Shutterstock: Ralwel
• Source: Shutterstock: Ralwel

Approval in 2011 of Bristol-Myers Squibb Co.'s CTLA-4 checkpoint inhibitor Yervoy (ipilimumab) in melanoma signaled the start of the immunotherapy revolution in the field of cancer therapy, followed by the PD-1 inhibitors and with new mechanisms nearing the market. Data presented at the Society for Immunotherapy and Cancer (SITC) annual meeting in November revealed that PD-1/L1 inhibitors such as Bristol's Opdivo (nivolumab) and Merck & Co. Inc.'s Keytruda (pembrolizumab) are being tested in about 1,500 clinical trials, of which 74% are evaluating combination approaches with other immunotherapies and traditional targeted agents. (Also see "Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well" - Scrip, 14 November, 2017.)

Development has been fueled by high unmet need and regulatory willingness to speed approvals for drugs aimed at life-threatening diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Innovation

Plans For A London Cancer Hub Promises New Destination For Biotech Innovation

 
• By Jo Shorthouse

Plans have been submitted for a £1bn development in London that can home biotech companies and encourages cross collaboration with the Institute of Cancer Research. In Vivo took an exclusive tour of the UK’s prospective new cancer innovation district.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

More from In Vivo